Daniel G. Fuster (@Dan_Fuster) header
Daniel G. Fuster (@Dan_Fuster) profile picture

Associate Professor of Nephrology @inselgruppe and @unibern. Kidney stone and rare kidney disease enthusiast. Passion for skiing, climbing and alpinism.

Switzerland
Joined March 2023
Photo by Daniel G. Fuster (@Dan_Fuster)Photo by Daniel G. Fuster (@Dan_Fuster)Photo by Daniel G. Fuster (@Dan_Fuster)Photo by Daniel G. Fuster (@Dan_Fuster)Photo by Daniel G. Fuster (@Dan_Fuster)Photo by Daniel G. Fuster (@Dan_Fuster)
Daniel G. Fuster retweeted
Best video I’ve seen all day. Congratulations Dr Deisseroth
The most important briefings of the day. Karl Deisseroth, professor of bioengineering and of psychiatry and behavioral sciences, shares the news of his Nobel Prize with his kids.
1
3
1
18
3,819
Daniel G. Fuster retweeted
My (devil's advocate) perspective: Henderson-Hasselbach & Stewart are equivalently accurate for clinical diagnosis & management of acid-base abnormalities. Stewart is fine, but it causes people to speak a different language that leads to confusion (most clinicians use H-H). People mess up acid-base because they aren't paying attention (e.g., ignoring an elevated anion gap or a low bicarb). I'm always surprised by how a potassium of 3.4 mM causes alarm, but a bicarb of 14 mM is often ignored. Transitioning from H-H to Stewart will make you seem fancy and smart, but it won't improve your clinical acumen. If anything, it will slow you down. The best approach to clinical acid-base is a simple model that is widely utilized (H-H) and easy to apply broadly and uniformly (e.g., this approach emcrit.org/ibcc/agma/).
Part 2 of the acid–base series will be out tomorrow on thedependentvariable.com This one is entirely about the chemistry behind Stewart: strong ions, weak acids, SID, electroneutrality, where the H⁺ comes from, and what “independent” and “dependent” variables actually mean. I wanted to take the time to explain the bits that are usually skipped over. Part 3 will then bring it all back to the bedside.
7
16
1
113
21,952
Daniel G. Fuster retweeted
Our new study is just published! We identified an association in >300 people, then followed up in mice and cells. Our findings point to a new potential hormonal cascade whereby high salt intake increases cortisol, which may suppress FGF23. Link: doi.org/10.1007/s00424-026-0…
2
5
77
Daniel G. Fuster retweeted
New mechanistic piece of the SGLT2 puzzle: direct activation of PANK1 in the human heart → ↑CoA → improved cardiac energetics and function. The kidney–heart understanding just became even more interesting. Science science.org/doi/10.1126/scie…
2
14
600
Daniel G. Fuster retweeted
Klotho, the "longevity protein," has long been a black box — we knew kidneys produced it, but not how it worked. #CityUHK Professor Ganesh Pathare, in collaboration with Professor Johannes Loffing, from the University of Zurich, have finally mapped its precise kidney functions - cracking the code! 🔑 Two game-changing discoveries: 🌟 Distal tubule Klotho → regulates calcium & bone health 🌟 Proximal tubule Klotho → maintains phosphate & circulating sKlotho levels Overturning long-held assumptions, this study opens new doors for treating chronic kidney disease! 🩺 🔗 Read more: go.cityu.hk/tlivyt
3
1
3
452
Daniel G. Fuster retweeted
A couple of highlights of the 63th ERA Congress held in Glasgow last week are presented in the M@H recording which will be streamed tomorrow evening (7:30 pm CET) - in-depth and more detailed discussions of the presented trials. youtube.com/watch?v=OxbYH9yO…
5
16
1,189
Daniel G. Fuster retweeted
It was a huge pleasure to work alongside a global team and contribute to the CKD series published in @TheLancet (article 1 out of 3). thelancet.com/series-do/chro…
3
39
1
124
7,197
Daniel G. Fuster retweeted
Obinutuzumab shows significant efficacy in active SLE.
Original Article: Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus (phase 3 ALLEGORY trial) nejm.org/doi/full/10.1056/NE… #SLEuro | @SLEuroSociety
3
7
655
Daniel G. Fuster retweeted
Join this global initiative, CRESCENDO, which collects data on patients with crescentic lesions on their kidney biopsy. Reach out to one of the team members. 6 continents, over 100 centers have registered already! academic.oup.com/ckj/advance… @AnnetteBruchfe1 and Vanja Ivkovic
1
13
39
2,555
Daniel G. Fuster retweeted
🚀 STOP-PKD-News! Das zweite Prüfzentrum in Mainz ist nun offiziell freigegeben. Weitere folgen (DE, NL, ES, AT). Kann SGLT2-Inhibition das Fortschreiten von Zystennieren positiv beeinflussen? Infos und Kontakte: stop-pkd.de/ #STOPPKD #ADPKD @PKD_Int
1
3
192
I am glad to work together with leading experts in the field of rare kidney diseases! Together these diseases are common! Thank you @GlomCon
🚨 We are pleased to announce the upcoming launch of GlomCon’s Rare Kidney Disease Journal, a new peer-reviewed journal developed in partnership with @SpringerNature. This journal will serve as a global platform dedicated to advancing research, clinical practice, and innovation in rare and complex kidney diseases.
12
11
52
3,539
Daniel G. Fuster retweeted
Replying to @Tobias_B_Huber
Thank you, dear Tobi — your friendship and leadership mean a great deal. No one advances alone; we are all part of a shared mission to understand and ultimately eliminate kidney disease. The future of nephrology is bright when science, collaboration, and vision come together.
3
13
503
Happy to see our review on "challenges" in ANCA-associated vasculitis published in @NatRevRheumatol! A special thanks to the Editorial Team and also @martacasalmoura for leading this initiative! #vasculitis @EUVAS19 @vasculitides
New content online: Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis bit.ly/4njE0hq
37
102
10,685
Daniel G. Fuster retweeted
Congratulations Biff. Well deserved
ASN Kidney News Oct/Nov 2025 Biff F. Palmer to Receive Robert G. Narins Award for Contributions in Education kidneynews.org/view/journals… @asnpublications
1
5
618
Congrats to ⁦@samirparikhmd⁩ and team⁩ for a breakthrough paper in ⁦@ScienceMagazine⁩ showing that somatically acquired heteroplasmic mtDNA mutations are a cause of chronic kidney disease and are functionally reversible. ⁦⁦@ASNKidney⁩ ⁦@the_asci⁩ 👇👇
3
21
1
67
9,230
The inaugural YNA meeting came to an end! @sara___helena must be commended for the visibility of #YNA!
3
4
27
1,626
YNA Symposium Day 1 was a success🎉🫘☺️ @YNAnephro – at Vienna, Austria
3
11
629
Congratulations to @milena_bond and the Firenze Team!
New article! Predictors of remission and relapse in retroperitoneal fibrosis. ➡️ Metabolic activity of RPF at 18F-FDG-PET is an important predictor of remission and relapse. 🔗doi.org/10.1111/joim.70017 #IgG4 #PET #retroperitonealfibrosis #vasculitis #medtwitter @UNI_FIRENZE
1
1
11
975